Head of Regulatory Science & Policy EU/AMEE
Sanofi
Reading, England, United Kingdom
Rebecca joined Sanofi in 2022 to lead their regulatory science and policy efforts in Europe, Africa and the Middle East and coordinate specific global projects with a goal of fostering new approaches for early access of medicines for the benefit of patients. Focus areas include optimising the European regulatory environment, expedited regulatory pathways, regulatory convergence, digital transformation and adapting regulatory frameworks to new science and in support of innovative technologies. She is the Chair of the EFPIA European Regulatory Affairs & Operations (ERAO) committee, sits in an EMA Focus Group and is a member of the Regulatory Optimisation Group (ROG) & co-leads a workstream in the IDERHA (Integration of Heterogeneous Data and Evidence towards Regulatory and HTA Acceptance) IHI consortia.
Before joining Sanofi, Rebecca was a Director in the Global Regulatory Policy & Intelligence team at Pfizer and also held the role of Co-Chair of the FIFARMA’s Regulatory and Biologics Working Group (2020-2022). Her career has included 8 years at the UK Trade Association (ABPI) working on numerous policy issues relevant to the biopharmaceutical industry including science and innovation policy. She was a post-doctoral scientist prior to her career in policy, with a PhD from Fitzwilliam College, University of Cambridge (UK) in cell signalling.
Disclosure information not submitted.
Preconference Workshop: EU Pharmaceutical Regulatory Reform
Tuesday, May 13, 2025
08:30 - 16:00 CEST
EU Pharmaceutical Regulatory Reforms – Time to Consider Implementation Challenges and Opportunities?
Wednesday, May 14, 2025
08:30 - 09:30 CEST
Plenary Session - Disruptive Innovation: Redefining Regulatory Roles
Friday, May 16, 2025
08:30 - 10:00 CEST